Juvente
From page 10 of the management circular.
A second generation of JuventeDC products with higher concentration of beta glucan was launched in Q4, 2020 and is going to be assessed in targeted European markets. Based on previous observations and on the successful development of new chemical complexes like oat beta glucan impregnated with Co-enzyme Q10 (CoQ10-iBG), and using our PGX technology, we expect to develop several combinations of bioactive substances to be included in a JuventeDC line of cosmeceutical products. Some of them like anti-inflammatory products and cannabinoids for which Ceapro was granted a five-year research license by Health Canada in 2020, would potentially necessitate a prescription by a healthcare professional.